Agoracom Blog Home

Posts Tagged ‘weed’

North Bud Farms $NBUD.ca Announces the Appointment of Sean Homuth as Acting Chief Financial Officer $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 10:03 AM on Thursday, October 17th, 2019
  • Announce the appointment of Sean Homuth as Acting Chief Financial Officer, effective today
  • Mr. Homuth’s permanent role as CFO will commence upon receiving Health Canada security clearance required for all Officers and Directors of the Company

TORONTO, Oct. 17, 2019 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce the appointment of Sean Homuth as Acting Chief Financial Officer (CFO), effective today. Mr. Homuth’s permanent role as CFO will commence upon receiving Health Canada security clearance required for all Officers and Directors of the Company. 

“As NORTHBUD expands its presence into the USA with the anticipated closing of its previously announced letters of intent with the Qlora Group (California) and Nevada Botanical Science (Nevada), we are strategically adding additional expertise in international business and finance,” said Ryan Brown, CEO of North Bud Farms Inc.

Mr. Homuth brings extensive experience with both Canadian and U.S. publicly traded organizations both in industry as well as from a client perspective during his tenure at Ernst & Young and, more recently, as an independent consultant. Previously, Mr. Homuth was Chief Financial Officer at Orezone Gold Corporation (and Vice President, Finance and Administration for its predecessor company, Orezone Resources Inc.) a publicly listed company headquartered in Canada with operations in West Africa. At Orezone Mr. Homuth led a global team of finance professionals and was involved in over $800 million in financings and M&A transactions with the company and its predecessor. Mr. Homuth holds accounting designations in both Canada (CPA, CA) and the United States (CPA – Illinois).

“We are pleased to welcome Sean to our dynamic team as NORTHBUD expands its footprint into the USA,” stated Ryan Brown, CEO of North Bud Farms Inc. “Sean brings specialty experience in accounting and finance for international companies as well as a profound knowledge of capital markets, having worked with and advised many public companies over the years. He joins NORTHBUD at an exciting time in its development as his leadership and experience will be essential in executing our strategic plan and taking the company to its next level of growth.”

Brendan Stutt, the Company’s incumbent CFO, who has made invaluable contributions to the Company’s financial leadership and culture, will work to ensure a smooth transition and will remain with the Company in a non-executive role.

Mr. Brown stated: “We would like to thank Brendan for his contributions to the Company, in particular the successful listing of NORTHBUD on the Canadian Securities Exchange.” 

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a licence under The Cannabis Act. The Company has built a state-of-the-art purpose-built cannabis production facility located on 135 acres of Agricultural Land in Low, Quebec, Canada. NORTHBUD through its wholly owned U.S. subsidiary, Bonfire Brands USA has entered into agreements to acquire assets in California and Nevada.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements and information included in this press release that, to the extent they are not historical fact, constitute forward-looking information or statements (collectively, “forward-looking statements”) within the meaning of applicable securities legislation. Forward-looking statements, including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. This press release contains forward- looking statements including those relating to the entering into of the Definitive Agreement and closing of the Transaction with the Qlora Group and Nevada Botanical Science. Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risk factors included in the Company’s final long form prospectus dated August 21, 2018, which is available under the Company’s SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Bougainville Ventures $BOG.ca – CBD Demand Soars With a Growing Number of Uses $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 1:27 PM on Tuesday, October 15th, 2019

SPONSOR:  Bougainville Ventures Inc (CSE: BOG) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

CBD Demand Soars With a Growing Number of Uses

  • Global cannabidiol market is expected to grow from USD 1.04 Billion in 2018 to USD 16.32 Billion by 2026 while registering a CAGR of 27.7% during the forecast period, according to data compiled by Reports and Data

NEW YORK, Oct. 15, 2019 – As the medical industry continues to evolve, researchers are actively looking for innovative remedies and treatments for patients. Notably, cannabis has become the topic of discussion after numerous researchers and institutions highlighted its therapeutic benefits. However, despite medical advancements throughout the cannabis industry, most federal regulators around the world have not yet moved to fully legalize cannabis for medical applications because of the psychotropic effects associated with it. Nevertheless, several regulators have decided to legalize cannabidiol, or CBD, a compound found within cannabis. CBD is a derivative found within the cannabis plant, however, unlike its tetrahydrocannabinol, or THC, counterpart, it does not induce psychoactive effects. Consequently, regulators became more inclined to legalize CBD. Primarily, the CBD industry is being accelerated by the healthcare segment.

Specifically, countries such as Australia, Canada, France, Germany, Italy, the U.K. and the U.S. have all adopted CBD-related legislation. Overall, the therapeutic grade segment dominates that overall CBD market because of increasing demand from innumerable applications. The segment accounted for 58.6% of the overall CBD market share and is expected to continue its dominance. In particular, the healthcare segment is expected to account for a total of USD 10.28 Billion of the CBD market by 2026. Moreover, the food and beverage industry is also expected to witness exponential growth. And while the U.S. and Canada are the primary drivers for the global CBD market, other international markets are also expected to greatly contribute. For instance, the Asia Pacific market is anticipated to reach USD 3.1 Billion by 2026 and exhibit a CAGR of 29.5%, while the European market is projected to grow at a CAGR of 28.9%. As a result, the global cannabidiol market is expected to grow from USD 1.04 Billion in 2018 to USD 16.32 Billion by 2026 while registering a CAGR of 27.7% during the forecast period, according to data compiled by Reports and Data.

The pharmaceutical segment of the CBD industry is expected to witness significant R&D investments to accelerate deployment and meet the medical needs of a number of diseases. Specifically, researchers have uncovered that CBD can treat a variety of diseases such as chronic pain, anxiety, depression, and cancer. And while most of these conditions would likely require a prescription from a medical practitioner, there are over-the-counter or OTC products that consumers can easily purchase at their local convenience stores in the U.S. or Canada. Consumers can purchase CBD-based products such as tinctures, topicals, patches, capsules, foods, and beverages. Typically, most OTC products are marketed as health and wellness products that are aimed to relieve minor ailments. For instance, many health and wellness retailers promote CBD as a way to stimulate relaxation or relieve small headaches. Notably, major pharmaceutical retailers such as CVS or Walgreens have also decided to add CBD products to their shelves. The two corporations added CBD products in order to provide consumers with cheaper and alternative care products. “It really does help normalize this. If Grandma can go to the store and get it, now the conversation about cannabis is going to be very different,” said Michele Ross, PhD, MBA, Research Director at Decriminalize California. “CBD business is already huge. But normalizing the culture around taking these products is going to open the door for more people to feel comfortable investing in these types of businesses. It opens up the possibility for them to be sold in more stores.”

Source: https://www.prnewswire.co.uk/news-releases/cbd-demand-soars-with-a-growing-number-of-uses-815946592.html

The Miracle That Is #CBD, Might Help Breast Cancer Patients Too – SPONSOR: Empower Clinics $CBDT $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 12:08 PM on Friday, October 11th, 2019

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics
  • Patient database of over 165,000 patients 
  • Platform generating $4MM USD in revenue annually (2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Launching CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

The Miracle That Is CBD, Might Help Breast Cancer Patients Too

By: Erika W. Smith  

CBD is in our lattes, moisturizers, and chocolates, but what about its use in a hospital setting instead of your local café or beauty store? Although more study is needed, research suggests that CBD may have the potential to help relieve certain side effects of chemotherapy.  

CBD is short for cannabidiol, which is one of the many compounds found in cannabis and hemp. Unlike tetrahydrocannabinol (THC), it’s non-psychoactive. Manufacturers have found a way to separate CBD from the plants, and the Agriculture Improvement Act of 2018 (aka the Farm Bill) legalized hemp-derived CBD that contains no more than 0.3% THC and is made from hemp grown by licensed producers. (That’s why you’ve seen so many CBD products recently.) But so far, the Food and Drug Administration has only approved one form of CBD: Epidiolex, a drug containing a purified marijuana-derived form of CBD, which is used for preventing seizures caused by rare forms of epilepsy. 

However, medical marijuana — which contains CBD as well as THC and other compounds — has been used by cancer patients for many years. In 1996, California became the first state to legalize marijuana for medical use. And although marijuana is still illegal on a federal level, it’s currently legal for medical use in 33 states — and it’s approved for use by cancer patients in every state in which medical marijuana is legal. (For comparison, medical marijuana is approved for use by patients with Crohn’s disease in only 27 states.) Additionally, the FDA has approved two chemically pure drugs based on marijuana compounds to treat nausea and vomiting in cancer chemotherapy patients.   

A 2016 review of medical marijuana’s use in oncology, published by the American Medical Association journal JAMA Oncology, notes, “Marijuana in oncology may have potential for use as an antiemetic [relieving nausea and vomiting], for refractory cancer pain, and as an antitumor agent. However, much of the data are based on animal data, small trials, or are outdated.” The authors concluded that more research is needed into medical marijuana’s therapeutic use for cancer patients.  

There is even less research into CBD’s potential benefits for cancer patients. But still, some studies have been conducted. According to the National Cancer Institute, research indicates that CBD may slow the growth or reduce the risk of recurrence of certain kinds of cancers, including breast cancer; enhance the potency of certain medications; and reduce chemotherapy side effects including vomiting, nausea, and anxiety. However, all these studies are limited, and experts agree that further research is needed to understand just how CBD affects humans.  

Source: https://www.refinery29.com/en-us/cbd-oil-breast-cancer

Empower Clinics $CBDT.ca Provides Corporate Updates Highlighting Triple Digit Patient Growth and Subsidiary Sun Valley Health Launches New Modalities and Patient Services $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 7:43 AM on Thursday, October 10th, 2019
  • Patient visits in corporate clinics increase by triple digits, with September 2019 patients seen increasing by 307% to 1,884 versus September 2018 with 614 patients seen
  • Launching seven new modalities and services for patients in the Sun Valley Health clinics

VANCOUVER, Oct. 10, 2019  – EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, a multi-state operator of medical health & wellness clinics, a CBD product producer and operator of an extraction facility in Oregon, is pleased to announce it is launching seven new modalities and services for patients in the Sun Valley Health clinics commencing Monday October 14th, 2019.

The Company also has patient visits in corporate clinics increase by triple digits, with September 2019 patients seen increasing by 307% to 1,884 versus September 2018 with 614 patients seen.

“The tremendous year-over-year increase in patient visits is a testament to the operating strengths and patient management demonstrated by our clinic team members, each and every day,” said Steven McAuley, CEO of Empower. “Their passion for patient wellbeing and the use of numerous communication tools ensures world-class service is provided throughout the entire patient journey.”

As part of the Company’s continued expansion of our health & wellness clinic model, we have already set up retail CBD product sales in-clinic, and now we have launched expanded physician based services.

New Modalities and Services

  • Physician’s CBD Enhanced Massage, Acupuncture, or Cupping Sessions
  • CBD-Cannabis-Supplement Consumption & Coaching Consultation
  • Introduction to Alternative Health and Cannabinoid Therapies by a Physician
  • Comprehensive Naturopathic Patient Analysis & Consultation
  • Dietary Antigen Testing, Physician Consultation/Action Plan, & Concierge Blood Draw
  • Neurotransmitter (urine) Profile & Physician Consultation/Action Plan
  • Spectracell Micronutrient Test & Physician Consultation/Action Plan

“By offering our new suite of laboratory testing, alternative health consulting, and CBD therapies we are able to address the needs of our current patients and serve the community outside of cannabis that are seeking alternative health care,” states Dustin Klein, Director & VP Business Development. “Incorporating our new modalities, high quality vitamins, supplements, and CBD products into our network of clinics is a natural progression toward our goal of becoming the nation’s premier alternative healthcare provider.”

Additional UPDATES

  • New Modalities and Patient Services The Company continues to see patient visits in corporate clinics increase by triple digits, with September 2019 patients seen increasing by 307% to 1,884 over July 2018 614 patients seen.

  • Sun Valley Health Franchise Sun Valley Health www.sunvalleyhealth.com has been actively participating in various franchise and cannabis expos in St. Louis, Chicago and Houston to market the Sun Valley Health franchise program, attracting numerous qualified candidates for available territory locations. The Company has accepted many applications and has provided the Franchise Disclosure Document (FDD) to qualified applicants in anticipation of completing the first initial territory sales.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

PODCAST: Why #cannabis 3.0 is the real opportunity for Canada with Bruce Linton – SPONSOR: #NORTHBUD $NBUD.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 12:55 PM on Wednesday, October 9th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

PODCAST: Why ‘cannabis 3.0’ is the real opportunity for Canada with Bruce Linton

By: Emily Jackson

Welcome to Down to Business, a weekly podcast from the Financial Post.

It’s been one year since Canada legalized the recreational cannabis industry after a century of prohibition. But it’s just the beginning of the journey from the black market to “cannabis 3.0.”

In the lead-up to the election, Down to Business has focused on business issues with a political twist. This week, host Emily Jackson discusses the cannabis industry’s one-year legalization anniversary with Bruce Linton, the former chief executive of Canopy Growth, Canada’s largest cannabis company.

Linton discusses lessons from the first round of legalization for recreational use, what to expect from the impending introduction of cannabis infused beverages and edibles, and why Canada needs to focus on “cannabis 3.0” if it wants to be a global leader.

You can listen below — or on Apple PodcastsSpotifyStitcher and Google Play, where you can also subscribe to get new episodes every Wednesday morning.

Source: https://business.financialpost.com/cannabis/cannabis-business/down-to-business-podcast-why-cannabis-3-0-is-the-real-opportunity-for-canada

Bougainville Ventures Inc. Appoints Mr. Andy Dhaliwal, President of Thrive Nutrition to Vice President of Sales and Distribution $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 7:54 AM on Tuesday, October 8th, 2019
  • Company has appointed Mr. Andy Dhaliwal, President of Thrive Wellness to Vice President of Sales and Distribution for Bougainville Ventures Inc. 

VANCOUVER, British Columbia, Oct. 08, 2019 — BOUGAINVILLE VENTURES INC. (CSE: BOG) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Bougainville” or the “Company”) is pleased to announce that further to the signing of the definitive agreement to complete the acquisition of Thrive Nutrition Products Ltd. (“Thrive Wellness”) announced in the Company news release dated September 24, 2019, the Company has appointed Mr. Andy Dhaliwal, President of Thrive Wellness to Vice President of Sales and Distribution for Bougainville Ventures Inc.  Thrive Wellness is a preeminent distributor of hemp & cannabinoid-focused natural health products under the “THRIVE WELLNESS” brand.

About Thrive Nutrition Products Ltd.
Thrive Wellness is a distributor of premium hemp and natural health products with operations currently in Canada and the USA. Thrive specializes in the development, marketing and distribution of cannabinoid products refined into their own natural health product brand. The company was founded in Vancouver, British Columbia and is the first of its kind with national retail distribution in Canada. Thrive has achieved $2,500,000 CDN in sales through retail distribution, its’ e-commerce website and their relationship with Nutrition House, Canada’s leading Natural Health Product franchise. Founded in 1979 the company began franchising in 1993 and now operates over 45 retail stores, located in high profile shopping centers across Canada, and in the USA. www.nutritionhouse.com

CEO, Andy Dhaliwal Comments:

“I am very excited to be a joining a team that is extremely well positioned for significant growth in the emerging cannabis & hemp markets. I look forward to helping Bougainville continue building shareholder value and to increase our international exposure through this partnership. I am particularly keen on the CBD opportunity in the U.S., where Bougainville already has resources available.”

Mr. Dhaliwal is a pioneering expert in the marketing of cannabis, hemp, and natural health products, and brings over 12 years of experience in the industry. In addition to serving as the CEO of Thrive Wellness, he was an advisor for the Province of British Columbia’s Cannabis Operations, where he advised on corporate development and sales optimization. 

To learn more about what this news means to the shareholders visit https://marketnewsfirst.com/bog-news, as well as on the company’s site.

About the CBD Market

Bank of America projects a spend of $1.3 Billion on CBD in Canada by 2022, while $1.9 Billion is being spent in the USA currently, and another $4.4 Billion in Europe this year. Demand for CBD and Hemp is increasing year over year, with Merrill Lynch predicting an $11.5 Billion American market by 2032.

About Bougainville Ventures, Inc.

Bougainville Ventures Inc. is dedicated to rapid growth in production, processing, retail and branding of cannabis and cannabis related products. Currently the company provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. We offer fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Also, the Company is focused on building a strong presence in the hemp industry with the objective of extracting cannabinoids in both Canada and the United States. Along with our flagship Hemp project in Oregon State and the Greenhouse campus in Washington State, the Company has proprietary formulas for cannabis edibles, topical, and tinctures.

On behalf of the Board of Directors
BOUGAINVILLE VENTURES INC.

Andy Jagpal, President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305 [email protected]. Or toll free at 1-877-517-7816

http://bougainvilleinc.com/https://twitter.com/bougainvilleincwww.thriveCBD.org

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

No regulatory authority has approved or disapproved the information contained in this news release.

Another First for the #Pot Industry: A Licensed Cannabis Restaurant SPONSOR: NORTHBUD $NBUD.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 10:01 AM on Monday, October 7th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–

Another First for the Pot Industry: A Licensed Cannabis Restaurant

  • Cannabis edibles are a growing segment of the market and are expected to reach $4.1 billion in 2022, combining Canadian and U.S. sales.
  • In 2017, that figure was just $1 billion among the two countries. The segment is going to be key to the industry’s long-term growth.

By: David Jagielski

Cannabis edibles are a growing segment of the market and are expected to reach $4.1 billion in 2022, combining Canadian and U.S. sales. In 2017, that figure was just $1 billion among the two countries. The segment is going to be key to the industry’s long-term growth.

Restaurants haven’t been able to take advantage of that growth since the U.S. Food and Drug Administration has still not permitted cannabidiol (CBD) to be infused into food. While the FDA has held hearings on CBD, there’s no indication that changes are coming anytime soon.

One restaurant, however, has been able to get around that problem. Lowell Farms opened its doors earlier this month in West Hollywood, Calf., and it’s the first restaurant with a lounge licensed for cannabis use. Customers will be able to eat food and consume pot at the same establishment. That doesn’t mean the restaurant will be able to make and serve cannabis food. Instead, cannabis edibles will be permitted only if they are “produced by an outside source.” 

One of the other restrictions the restaurant will face is not being able to sell alcohol to diners. It’s a small price to pay to let them consume cannabis, since pot lounges remain a rarity in the industry. Las Vegas is among the cities looking at permitting such lounges, but that could be years away because there’s still a lot of opposition to it. 

Will a bar someday be a place to enjoy pot with friends? Image source: Getty Images.

Why lounges could be big for the industry

While marijuana has been legalized in many parts of the U.S., that doesn’t mean it’s possible to consume it at bars or sporting events, unlike alcohol where there are many places that users can drink in a social setting. Allowing that could unlock another avenue of growth for the industry.

Cannabis beverages are on the rise and expected to grow globally at a rate of more than 15% per year from now until 2025, reaching $4.5 billion in market size by then. So there’s going to be a growing need for places to enjoy such drinks with friends without always having to do so at home. And that doesn’t even factor in the growth of edibles that could be consumed at lounges, such as candy, cookies, and chocolate.

In Canada, there’s potential for Canopy Growth to test its products in one lounge that was made legal earlier this year. In many ways, the emerging Canadian cannabis edibles market, which is going to be legalized later this month and where the first products will be available in December , could prove to be a good indicator of how successful some of these concepts will be in the U.S. And for Canopy Growth, it could be an important way to get closer to breakeven.

For now, Canopy Growth can be a good opportunity for investors to take advantage of the new edibles market in Canada. Not only is the company well-positioned for success in the beverages segment, but in a recent interview with BNN Bloomberg, CEO Mark Zekulin said the company was working on more than 50 different products for the edibles market. That could lead to significant growth for Canopy Growth and get investors excited about the stock once again.

Here’s The Marijuana Stock You’ve Been Waiting For

A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming.

Cannabis legalization is sweeping over North America – 10 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.

And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.

Because a game-changing deal just went down between the Ontario government and this powerhouse company…and you need to hear this story today if you have even considered investing in pot stocks.

Source: https://www.fool.com/investing/2019/10/06/another-first-for-the-cannabis-industry-a-licensed.aspx

NORTHBUD $NBUD.ca – As Canada gears up for pot 2.0, more shortages are on the menu $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 12:07 PM on Thursday, October 3rd, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE
—————————–
  • Canada’s legalization of pot edibles later this year is facing an even more shambolic start than the dried flower market, which is still struggling to meet demand, according to industry players.

Kristine Owram, Bloomberg News

Canada’s legalization of pot edibles later this year is facing an even more shambolic start than the dried flower market, which is still struggling to meet demand, according to industry players.

“At least that time we knew what the permissible product types were going to be and were already making them in the medical context,” said cannabis lawyer Trina Fraser, a partner at Brazeau Seller Law in Ottawa.

Canada will add edibles, extracts and topicals to the list of legal cannabis products no later than Oct. 17. Many analysts agree these products will generate better demand and margins than dried flower. But the federal government has not yet issued regulations for the new formats, making it difficult for producers to prepare lest they unknowingly violate some rule.

A spokeswoman for Health Canada declined to comment on when the regulations will be released.

In addition, a huge licensing backlog has built up at Health Canada, the government agency that oversees cannabis regulations. About 614 applications were waiting in the queue as of March 31.

“A full rollout amongst a nice wide array of producers and a wide array of these new product types is going to take time, literally years, because we have such a licensing backlog,” Fraser said.

Company Stockpiling

Canada’s market for edibles and other alternative pot produces will eventually be worth C$2.7 billion ($2 billion) annually, but consumers should expect “missteps, delays and frustration” in the early days, Deloitte said in a report published Monday. Jennifer Lee, Deloitte Canada’s cannabis national leader, estimated it will be a minimum of 24 months before the industry normalizes.

In the meantime, many pot companies are stockpiling, choosing to forgo revenue today to ensure they have enough supply for the new high-value products. This is exacerbating the shortage of dried flower, but executives say it’s worth it.

“We’ve made a very conscious effort to delay revenue,” said Chuck Rifici, chief executive officer of Auxly Cannabis Group Inc. Selling into the market today doesn’t build brand recognition because shelves are empty and consumers are buying whatever’s available, he added. “I would much rather save that product, get a multiple of margin on that brand and make sure that I have enough inventory.”

Lab Delays

This is proving to be a boon for extraction companies like Valens GroWorks Corp. Valens has contracts with many of the biggest pot companies, including Canopy Growth Corp., Hexo Corp. and Tilray Inc., to extract cannabis oil from their plants, which is then used for products like edibles and vape cartridges. It’s also investing heavily in its testing labs in the belief that Health Canada will have stringent regulations to ensure pesticides and other contaminants don’t make it into the new consumer products.

“Even in labs today there’s delays where people are waiting three weeks to a month to get lab results back and I think that will only get worse,” said Everett Knight, Valens’ executive vice president of strategy and investments.

Companies are also making big bets on what products will be in demand, with Canopy and Hexo leaning toward cannabis beverages and others toward vaping.

Be Prepared

“Why do I want an edible or a drink when I can have a vape?” Irwin Simon, interim CEO of Aphria Inc., said in an interview on the sidelines of a cannabis conference last month. “I see the margins and the opportunities there.”

Rifici at Auxly also believes vape pens will be “the most important category by far.” But there are many unanswered questions. For example, will the government require companies to engrave its mandatory THC warning symbol into the pen itself, or will a sticker suffice?

This is why Valens is offering its customers 196 different options for its white-label vape pens. “You’ve got to make sure you cover your bases and prepare for all the possibilities,” Knight said.

Despite the uncertainty, it’s better to be prepared even if plans and production lines have to be tweaked once the regulations come out, said Bruce Linton, CEO of Canopy, which is building a 197,000 square foot bottling plant for cannabis beverages in Smiths Falls, Ontario.

“We’re in a situation where it’s better to spend money to be ready than to save money and be late,” he said.

 Cannabis Canada is BNN Bloomberg’s in-depth series exploring the stunning formation of the entirely new – and controversial – Canadian recreational marijuana industry. Read more from the special series here and subscribe to our Cannabis Canada newsletter to have the latest marijuana news delivered directly to your inbox every day.

Source: https://www.bnnbloomberg.ca/as-canada-gears-up-for-pot-2-0-more-shortages-are-on-the-menu-1.1268844

Benefits #CBD oil promotes for your health – SPONSOR: Empower Clinics $CBDT.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 12:03 PM on Wednesday, October 2nd, 2019

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics
  • Patient database of over 165,000 patients 
  • Platform generating $4MM USD in revenue annually (2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Launching CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

Benefits CBD oil promotes for your health

CBD oil is a much talked about product, it is a topic of hot conversation, it is in the news and everyone has an opinion! Some opinions are based on fact, others on assumption and there are a group of people who just do not know what to think at all. This article will attempt to provide you with some information as to the possible health benefits which can be derived from taking CBD oil. CBD oil has much recent research attached and there is also increasing testimony from those who regularly take the product for a number of very different conditions from which they are suffering.

The first point to mention is that CBD or to give it its chemical name, Cannabidiol, should not be confused with its sister chemical THC or Tetrahydrocannabinol. Both chemicals are derived from the cannabis plant which in itself has over 100 chemicals and although the two chemicals are similar in a sense, they differ in the way in which their atoms are put together. Here, in the UK, CBD is legal to purchase whether it be as an oil or as part of another preparation.  It is the THC which is not legal and any product containing CBD can only contain trace elements of THC at the most, in fact products can contain no more than 0.2% THC. Each country has their own rules and so if you are planning to use CBD anywhere else other than in the UK, you should check the legal status first.

CBD is extracted from the cannabis plant using different processes and each manufacturer will use their own particular method of extraction. When the CBD has been extracted, it will then be mixed with a carrier oil and it is then known as CBD oil.

Many people have conditions which cause them to be in serious pain or have quite debilitating symptoms. Sometimes conditions can be treated and sometimes they cannot be treated and instead they are managed by medication, which is not the best solution for a long term problem. CBD has shown promise in giving relief and even turning around certain conditions. Evidence for its effectiveness has come in anecdotal form from those who have used the product and it comes also with scientific back up for many conditions and as more and more research emerges with results, CBD is becoming a go to product of choice for many. So what conditions is CBD oil known to help?

  • Chronic pain can be significantly lessened
  • Anxiety can be relieved
  • Depression
  • Stress
  • Both rheumatoid arthritis and osteoarthritis
  • Seizures including epilepsy
  • Inflammation
  • Nausea
  • Chronic headaches and migraines
  • MS
  • Parkinsons
  • Alzheimers
  • Obesity
  • Cancers

And the list goes on, in fact conditions throughout the body can be addressed using CBD oil.

It is not something that we are used to as when we are given ‘a pill for an ill’, we would not expect to receive the same pill for a headache and an infection for example, yet CBD would appear to treat and relieve many non similar conditions, the following provides an explanation as to why that is the case.

Our body is a complex series of structures which we have grouped into systems, we have the Nervous system, the Cardiovascular system, the Immune system and so on but one system which was only discovered around 30 years ago is the Endocannabinoid system. This system is the system which is responsible for bringing about an equilibrium or balance to the body, sometimes referred to as homeostasis. It does this via cannabinoid receptors. These receptors look for cannabinoids to attach to them and when they are satisfied that they have their requirement, the balance is restored and as long as the supply and uptake is maintained, so is the balance. When the system becomes unbalanced, the receptors are not fulfilled and when that balance is no longer there, illness and pain are felt. The body naturally produces its own endocannabinoids, sometimes it will not produce enough and sometimes the endocannabinoid being produced fail to reach the receptor points. CBD is a cannabinoid and it is thought that it works with the bodies own system to satisfy the receptors. This is why CBD can be used for all manner of illnesses and difficulties within the body. It can even be used in lower doses by healthy people to keep their system in check and many use it for this purpose.

Each person will have a dose that suits them best and it is up to each user to find that dose. It is always tempting to read about all of the good that a product has to offer and go about taking a high dose to try to access some of that good but this is the wrong way to go. Start with a small amount and gradually increase the amount until you feel a benefit. At that point, that should be the dose that suits you. Start with the weakest preparation and if you need to move to a stronger preparation, do that next. Do not assume that you will be able to copy the dose that someone else is taking, that is just not true, you have to work slowly to find your own.

Source: https://augustafreepress.com/benefits-cbd-oil-promotes-for-your-health/

The Top Most Compelling Reasons to Invest in the #CBD Market – SPONSOR: #Bougainville Ventures $BOG.ca $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 10:52 AM on Wednesday, October 2nd, 2019

SPONSOR:  Bougainville Ventures Inc (CSE: BOG) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

The Top Most Compelling Reasons to Invest in the CBD Market

  • According to Grand View Research, the global CBD market could see a compound annual growth rate of 32.6% to $9.7billion by 2025.
  • The firm also projects that the global CBD skincare segment of the market could grow at a CAGR of 33% to $1.7 billion by 2025.

The CBD boom is here, and it’s thriving especially as major retailers just on board.  Already, Neiman Marcus, Sephora, Vitamin Shoppe, Kroger, Barney’s DSW, CVS, American Eagle, and Walgreen’s are selling CBD products. Even Shopify is now offering features for U.S. retailers of hemp and CBD, expanding its North American reach. On top of that, support for cannabis legalization is exploding. For example, a Gallup survey found that 66% of Americans are in favor of legalization. That’s up from just 60% in 2016. In addition, according to Grand View Research, the global CBD market could see a compound annual growth rate of 32.6% to $9.7billion by 2025. The firm also projects that the global CBD skincare segment of the market could grow at a CAGR of 33% to $1.7 billion by 2025.

Read More: https://www.baystreet.ca/stockstowatch/6528/The-Top-Most-Compelling-Reasons-to-Invest-in-the-CBD-Market